Phase 3 Children’s Eczema (Atopic Dermatitis) Study
Now Open in Baton Rouge
● Now Enrolling
Atopic dermatitis (AD), also known as eczema, is a common skin disorder. Symptoms can include flaky skin lesions and intense itching. An estimated 20% of children suffer from AD, which can unpredictably flare in adolescence and in adulthood.
Children with mild or moderate atopic dermatitis (a.k.a. eczema) may be eligible to join this research study to test a new drug for the condition. This study treatment is experimental, and you (or your child) will have a 1 in 3 chance to be part of the placebo arm of this study. Compensation is available for study related time and travel.
Eligible participants…
- Must be age 2 to 5
- Must have had a history of atopic dermatitis (eczema) for at least 6 weeks
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for your child.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Study Location
Meridian Clinical Research
5326 O'Donovan Dr.
Baton Rouge, LA 70808
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.
© 2021 MERIDIAN CLINICAL RESEARCH, LLC | Privacy Policy